Will Icecure Medical stock go up?

According to Danelfin AI, Icecure Medical has today an AI Score of 1/10 (Strong Sell rating), because its probability of beating the market in 3 months (38.44%) is -12.37% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Icecure Medical stock?

The Icecure Medical target price is $27.12 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Icecure Medical stock right now?

Icecure Medical has today a Strong Sell rating (AI Score 1/10), according to Danelfin AI. Its probability of beating the market in 3 months (38.44%) is -12.37% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Icecure Medical stock is a good buy .

Is Icecure Medical undervalued right now?

Based on analysts, the average price target upside for Icecure Medical is +411.74% (1Y). According to Danelfin AI, Icecure Medical has today an AI Score of 1/10 (Strong Sell Rating).

What was the price range of Icecure Medical stock over the past 12 months?

The Icecure Medical stock price range over the past 12 months has been $2.13 - $35.7.

What is going on with Icecure Medical stock in the last 3 months?

The Icecure Medical stock performance in the last quarter has been -41.30%.

Does Icecure Medical offer dividend payments?

No, Icecure Medical does not currently pay dividends.

What is the current market capitalization of Icecure Medical?

Icecure Medical's market cap is $14.82M, as of 2026-07-02 08:00.

When is the next ICCM earnings report date?

ICCM will publish its next earnings report on 2026-05-12.

Icecure Medical Ltd (ICCM) AI Stock Analysis

Advanced Chart

Custom range

Jul 3, 2025

→

Jul 3, 2026

Custom range

Jul 3, 2025

→

Jul 3, 2026

ICCM AI-Powered Stock Analysis

AI Score Explanation

AI Score

Strong Sell

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Icecure Medical Ltd today receives an AI Score of 1/10, which translates to a Strong Sell rating. The stock has a 38% probability of outperforming the market in the next 3 months, which is 13% lower than the average probability of any stock (51%). The top positive contributor is the Chart Pattern (90d), which adds +0.58% to the probability. On the negative side, the top detractors include the Industry (GICS) (Health Care Equipment & Supplies) reducing probability by -1.49%, Institutional Ownership at bottom 20% (impact -1.09%), and the Fear & Greed Index at 31 (impact -0.90%). Other notable detractors are Maximum Volatility in the top 10% (-0.83%), Operating Profit Margin in the bottom 10% (-0.68%), and Long-Term Debt Coverage Ratio in the bottom 10% (-0.62%). Notable data points include a Performance (YTD) of -71% (bottom 10%), which surprisingly contributes positively (+0.57%), likely due to mean-reversion expectations. However, the stock exhibits extreme volatility with Maximum Volatility in the top 10% and Normalized Average True Range (180d) also in the top 10%, indicating high risk. Fundamental weaknesses are evident: Operating Profit Margin is -466% (bottom 10%), Long-Term Debt Coverage Ratio is -854 (bottom 10%), and Tangible Shareholders' Equity is in the bottom 40%. The net effect of all signals is -12%, aligning with the Strong Sell rating. Overall, the stock faces significant headwinds from poor fundamentals and high volatility, outweighing any minor positive technical signals.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Growth+0.29%
Expected pace of revenue and earnings expansion

Sentiment-3.54%
How analysts and the market view the stock
Valuation-2.58%
How the stock is priced relative to its fundamentals
Momentum-2.39%
Direction and strength of recent price movements
Volatility-2.09%
How much the stock price tends to fluctuate
Size & Liquidity-0.77%
Company size and trading liquidity
Profitability-0.68%
Profitability and operating efficiency metrics
Financial Strength-0.62%
Balance sheet strength and financial resilience

ICCM probability advantage of beating the market (3M):

-12.37%

AI Score

Strong Sell

Icecure Medical (ICCM) has an AI Score of 1/10 (Strong Sell) because, according to an overall analysis, it has a probability advantage of -12.37% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of ICCM (38.44%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
ICCM probability advantage of beating the market (3M)-12.37%
ICCM probability of beating the market (3M)38.44%

ICCM probability advantage of beating the market (3M): -12.37%

The AI-powered overall analysis of Icecure Medical (ICCM) is based on the 29 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of ICCM:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Sentiment	Industry (GICS)	Health Care Equipment & Supplies	N/A	-1.49%
Sentiment	Institutional Ownership	3.84%		-1.09%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.90%
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	-0.84%
Technical	Maximum Volatility	33.69%		-0.83%
Fundamental	Tangible Shareholders' Equity	8.49		-0.77%
Fundamental	Beginning Cash (Millions)	8.9		-0.77%
Technical	Distance from KAMA (20d)	0.41%		-0.75%
Technical	Chart Pattern (180d)	figure_52	N/A	-0.70%
Fundamental	Net Property, Plant & Equipment (Net PP&E)	0.98		-0.70%
Fundamental	Upgrade to unlock			-0.68%
Technical	Upgrade to unlock			-0.67%
Fundamental	Upgrade to unlock			-0.62%
Technical	Upgrade to unlock			-0.61%
Technical	Upgrade to unlock			+0.58%

Rest of Alpha Signals: -1.52%

ICCM probability advantage of beating the market (3M)Total:-12.37%
ICCM AI Score

Significant changes Vs previous day

ICCM Short Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$5.30
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro)
Take Profit:$XXXXXPro (XXXXX
Pro
)

ICCM Proven Sell Signal & Price Forecast

This is the price chart for ICCM from January 1, 2026 until today. The chart indicates, in red, the 92 days when the stock received a Sell/Strong Sell rating (sell signals, AI Score 1 to 3).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Sell signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Sell signals

Forecast:

1 Month
3 Months
6 Months
1 Year

ICCM Average Past Performance & Loss Rate

Three months after its 331 Sell signals since July 2026, ICCM had an average performance of xxxxxx and a xxxxxx Loss rate (negative performance).

331 Past ICCM Sell Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+248.78%
Average Alpha				+227.91%
Loss Rate (% Negative Perf.)				57.07%
% Negative Alpha				84.82%

ICCM Frequently Asked Questions

Will Icecure Medical stock go up?
According to Danelfin AI, Icecure Medical has today an AI Score of 1/10 (Strong Sell rating), because its probability of beating the market in 3 months (38.44%) is -12.37% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Icecure Medical stock?
Is it a good time to buy, sell, or hold Icecure Medical stock right now?
Is Icecure Medical undervalued right now?
What was the price range of Icecure Medical stock over the past 12 months?
What is going on with Icecure Medical stock in the last 3 months?
Does Icecure Medical offer dividend payments?
What is the current market capitalization of Icecure Medical?
When is the next ICCM earnings report date?

Icecure Medical Ltd Company Profile

IceCure Medical Ltd is an advanced-specimen medical equipment company, widely recognized in the sectors of research, design and provision of innovative medical devices for cryoablation - a technique used for freezing tumors within the human form. This groundbreaking service includes the offering of the ProSense system: an exclusive singular probe system that specifically commits to breast tumor treatments. Additionally, they provide the IceSense3 system designed for varying ablation applications, contributing significantly to an array of specialists including urologists, oncologists, dermatologists, gynecologists and surgeons spanning general surgery to thoracic practices and proctology. Instituted in 2006, IceCure Medical Ltd established its corporate headquarters in Caesarea, Israel where it continues to advance its revolutionary solutions across medical boundaries.

Sector:
Country:Israel
Industry:
Address:7 Ha'eshel St., PO Box 3163, CAESAREA
Employees:68
Website:icecure-medical.com

Pros

High switching costs for installed medical systems

Proprietary cryoablation technology intellectual property

Expanding clinical indications for cryoablation therapy

Demand for minimally invasive oncology procedures

Recurring revenue model from disposable probes

Cons

Extensive regulatory approval pathways for medical devices

Uncertainty in medical procedure reimbursement coverage

High capital expenditure for research and development

Competition from established and emerging cancer treatments

Dependence on physician training and adoption rates

Company	AI Score	Compare
ATRCAtriCure Inc
NVCRNovocure Ltd
PROFProfound Medical Corp
ICUIICU Medical Inc
CCELCryo-Cell International Inc

Company	AI Score	Compare
ATRCAtriCure Inc
NVCRNovocure Ltd
PROFProfound Medical Corp
ICUIICU Medical Inc
CCELCryo-Cell International Inc

ICCM Stock AI Analysis High Risk